Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, controls blood glucose and results in significant body weight loss in patients with type 2 diabetes. Beyond these well-known effects, an interesting aspect of this drug is its antiatherogenic activity, which should be further explored in clinical practice. This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drug's antiatherosclerotic properties. The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids. Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675489 | PMC |
| http://dx.doi.org/10.1186/s12933-021-01417-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Minimising harms of tight glycaemic control in older patients with type 2 diabetes.
Afr J Prim Health Care Fam Med
December 2024
Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.
In older adults with type 2 diabetes (T2DM), tight glycaemic control (HbA1c 7%) can result in more harm than benefit, especially when using insulin or sulfonylureas. Older adults are at higher risk for adverse drug events, especially hypoglycaemia, which may cause falls, confusion and hospitalisations. This Therapeutic Letter evaluates the risks of tight glycaemic control in older adults with T2DM, focusing on deprescribing diabetes medications in those over 65, especially those with multimorbidity and polypharmacy.
View Article and Find Full Text PDFNF-κB signaling is the major inflammatory pathway for inducing insulin resistance.
3 Biotech
February 2025
CSIR Institute of Genomics & Integrative Biology, Sukhdev Vihar, New Delhi, 110025 India.
Unlabelled: Insulin resistance is major factor in the development of metabolic syndrome and type 2 diabetes (T2D). We extracted 430 genes from literature associated with both insulin resistance and inflammation. The highly significant pathways were Toll-like receptor signaling, PI3K-Akt signaling, cytokine-cytokine receptor interaction, pathways in cancer, TNF signaling, and NF-kappa B signaling.
View Article and Find Full Text PDFDietary patterns related to triglyceride glucose index and risk of type 2 diabetes: a large-scale cohort study.
Front Nutr
January 2025
Department of Nutrition and Food Hygiene, School of Public Health, Nantong University, Nantong, China.
Background: Triglyceride glucose (TyG) index has been proposed as a credible and simple surrogate indicator for insulin resistance. The primary aim of this study was to novelly examine the associations between dietary patterns reflecting variations in circulating TyG index and the risk of type 2 diabetes mellitus (T2DM).
Methods: This study included 120,988 participants from the UK Biobank, all of whom completed multiple 24-h dietary assessments.
The relationship between perceived stigma and health-promoting self-care in adult patients with type 2 diabetes.
J Diabetes Metab Disord
June 2025
Institute of Health Sciences, Department of Medical Nursing, Sivas Cumhuriyet University, Sivas, Turkey.
Objectives: The study was conducted to examine the relationship between perceived self-stigma and health promotion self-care in patients with type 2 diabetes.
Methods: The study was conducted with 206 patients with type 2 diabetes who were hospitalized in the endocrinology clinic of a state hospital between July and September 2023 and met the study inclusion criteria. Data were collected using a patient identification form, the Type 2 Diabetes Stigma Assessment Scale (DSAS-2) and the Diabetes Health Promotion Self-Care Scale (DHPSC).
The PI3K/Akt pathway: a target for curcumin's therapeutic effects.
J Diabetes Metab Disord
June 2025
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Purpose: The purpose of this review study is to investigate the effect of curcumin on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway in various diseases. Curcumin, the main compound found in turmeric, has attracted a lot of attention for its diverse pharmacological properties. These properties have increased the therapeutic potential of curcumin in chronic diseases such as cardiovascular disease, Type 2 diabetes, obesity, non-alcoholic fatty liver disease, kidney disease, and neurodegenerative diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!